A Phase I Study of GTI2040 (NSC 722929; IND 67368) in Combination With High-dose Cytarabine in Refractory or Relapsed Acute Myeloid Leukemia (AML)

Trial Profile

A Phase I Study of GTI2040 (NSC 722929; IND 67368) in Combination With High-dose Cytarabine in Refractory or Relapsed Acute Myeloid Leukemia (AML)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Cytarabine (Primary) ; LOR 2040 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Mar 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
    • 02 Jul 2008 Results published in Clinical Cancer Research, reported by Lorus Therapeutics (9090722).
    • 30 Aug 2007 Status changed from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top